Imunon (NASDAQ:IMNN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Imunon (NASDAQ:IMNN) in a research note issued to investors on Monday morning,Benzinga reports. D. Boral Capital currently has a $29.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Imunon in a report on Thursday, December 19th.

Imunon Trading Up 12.1 %

Shares of IMNN stock opened at $1.07 on Monday. Imunon has a 12-month low of $0.64 and a 12-month high of $3.65. The company has a market cap of $15.57 million, a price-to-earnings ratio of -0.56 and a beta of 1.96. The stock has a 50 day simple moving average of $0.90 and a 200-day simple moving average of $0.92.

Institutional Investors Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC boosted its position in Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the period. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 as of its most recent SEC filing. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.